<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ann S LaCasce, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H16168373"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mantle cell lymphoma (MCL) is a mature B cell non-Hodgkin lymphoma with a variable clinical course. MCL can involve lymph nodes and extranodal sites, such as the gastrointestinal tract or blood and bone marrow. It is usually composed of small to intermediate size lymphoid cells that express BCL2, CD5, and nuclear cyclin D1, and lack CD23 expression. Nearly all cases have the t(11;14) chromosomal translocation, which fuses <em>CCND1</em> (which encodes cyclin D1) and the immunoglobulin heavy chain gene, resulting in overexpression of cyclin D1. Most patients with MCL present with advanced stage disease.</p><p>The pathobiology, epidemiology, clinical presentation, evaluation, diagnosis, and prognosis of MCL are discussed in this topic.</p><p>Management of MCL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4719.html" rel="external">"Mantle cell lymphoma: Initial management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Mantle cell lymphoma (MCL) accounts for 3 to 7 percent of non-Hodgkin lymphomas in the United States and Europe, with an incidence estimated to be 4 to 8 cases per million persons per year [<a href="#rid1">1-4</a>]. The incidence increases with age and appears to be rising in the US [<a href="#rid5">5</a>]. Median age at diagnosis is 68 years. Approximately three-quarters of patients with MCL are male, and White individuals are affected almost twice as frequently as Black individuals.</p><p class="headingAnchor" id="H3"><span class="h1">PATHOBIOLOGY</span><span class="headingEndMark"> — </span>MCL is associated with increased cellular proliferation, a blunted response to deoxyribonucleic acid (DNA) damage, and enhanced cell survival caused by impaired apoptosis  (<a class="graphic graphic_figure graphicRef73115" href="/z/d/graphic/73115.html" rel="external">figure 1</a>). Nearly all cases of MCL overexpress cyclin D1 due to the t(11;14), a chromosomal translocation that juxtaposes <em>CCND1</em> (the gene that encodes cyclin D1 at 11q13) with the immunoglobulin heavy chain gene joining region at 14q32 [<a href="#rid6">6,7</a>]. Overexpression of cyclin D1 fosters proliferation by overcoming cell cycle suppressive effects of RB and p27, thereby promoting the transition from G1 to S phase of the cell cycle [<a href="#rid8">8,9</a>].</p><p>Two distinct variants of MCL are recognized, the classic subtype and the non-nodal subtype, both of which are associated with the t(11;14). Classic MCL resembles immunologically-naïve mantle zone B cells, based on the presence of productive clonal rearrangements of the immunoglobulin heavy and light chain genes, expression of IgM and IgD, and lack of somatic hypermutation of immunoglobulin genes. By contrast, the non-nodal MCL subtype shows somatic hypermutation and has distinctive clinical and pathologic features [<a href="#rid10">10-14</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell cycle abnormalities</strong> – MCL cells exhibit increased cell division and replication. In nearly all cases, proliferation is driven by cyclin D1 overexpression, but rare cases are related to deregulation of cyclin D2 or cyclin D3.</p><p></p><p class="bulletIndent1">Cyclin D1, which is a regulatory subunit for cyclin dependent kinases (CDKs) 4 and 6, is not expressed by normal B lymphocytes [<a href="#rid15">15</a>]. Activated cyclin D-CDK complexes phosphorylate and inactivate retinoblastoma protein (Rb), an inhibitor of the G1 to S phase progression. This complex also binds cyclin dependent kinase inhibitor 1B (CDKI1B; also called Kip1 and p27) [<a href="#rid8">8</a>]. Binding of cyclin D1/CDK4 to CDKI1B stabilizes the complex and enhances proliferation.</p><p></p><p class="bulletIndent1">Up to half of patients with MCL demonstrate activation of the WNT signaling pathway, which stabilizes beta-catenin, allowing it to translocate into the nucleus and form a transcription complex that upregulates the expression of multiple target genes, including <em>CCND1</em> [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">Increased NOTCH signaling may also contribute to MCL cell proliferation by increasing MYC-controlled transcription through B cell-specific enhancers [<a href="#rid17">17</a>]. Increased MYC activity may also be related to stabilization of MYC protein through signals that require MALT1, a component of the CARD11-BCL10-MALT1 complex, which links B cell receptor (BCR) signaling to NF-kB [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enhanced cell survival</strong> – MCL cases display disturbances in pathways and factors that regulate apoptosis (programmed cell death) [<a href="#rid19">19,20</a>]. MCL cells avoid apoptosis through expression of BCL2, upregulation of the PI3 kinase (PI3K)/AKT pro-survival signaling pathway, activation of nuclear factor-kB (NF-kB), and loss-of-function <em>TP53 </em>mutations.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BCL2</strong> – BCL2, which enhances cell survival by blocking apoptosis, is overexpressed in more than half of cases of MCL [<a href="#rid21">21</a>]. Effects of BCL2 overexpression are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16646.html" rel="external">"Pathobiology of follicular lymphoma", section on 'Aberrant BCL-2 expression'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PI3K/AKT signaling</strong> – The PI3K/AKT signaling pathway promotes cell growth, survival, and tumorigenesis by inactivating CDKI1B/p27, BAD (a BCL2-related protein), and FOXO1 (a transcription factor that regulates the expression of pro-apoptotic genes) [<a href="#rid22">22,23</a>]. The PI3K/AKT pathway also increases NF-kB and mTOR (mammalian target of rapamycin), which reduces functional p53 and enhances cell survival. Abnormal PI3K/AKT signaling is often seen in MCL with blastoid morphology [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NF-kB</strong> – NF-kB comprises a family of transcription factors with important roles in regulating immune function. NF-kB is constitutively activated in a subset of MCL and in vitro treatment with an NF-kB inhibitor caused cell cycle arrest and apoptosis [<a href="#rid25">25</a>]. Recurrent mutations in NF-kB pathway components, TRAF2 or BIRC3, were found in 15 percent of 165 primary MCL tumors [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BTK</strong> – Bruton tyrosine kinase (BTK) functions downstream of membrane-bound BCR and links constitutive BCR signaling to PI3K/AKT activation and NF-kB activation. BTK inhibitors, such as <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a>, have single-agent activity in MCL [<a href="#rid27">27</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>p53</strong> – p53 is a tumor suppressor, encoded by <em>TP53</em>, that can induce apoptotic cell death. <em>TP53</em> mutations or deletions are associated with poor response to chemoimmunotherapy and adverse outcomes in MCL [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impaired DNA damage response</strong> – Some MCL cells have an impaired response to DNA damage that increases chromosome instability. This blunted response is largely due to defects in <em>TP53</em> and <em>ATM</em>, but some cases have decreased expression of the cell cycle checkpoint kinases 1 and 2.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RNA-binding proteins</strong> – Abnormal expression of RNA-binding proteins (eg, HNRNPH1) and associated perturbations of mRNA processing may also contribute to the pathobiology of MCL [<a href="#rid29">29</a>]. </p><p></p><p>Mutations found in MCL are discussed below. (See <a class="local">'Genetic features'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The clinical presentation differs among the two major subtypes of MCL: nodal MCL and leukemic, non-nodal MCL [<a href="#rid30">30,31</a>]. </p><p class="headingAnchor" id="H166296177"><span class="h2">Nodal MCL</span><span class="headingEndMark"> — </span>Nodal MCL accounts for at least three-quarters of cases of MCL. Most patients present with lymphadenopathy, but nodal MCL may also manifest splenomegaly and/or involve extranodal sites. Nodal MCL can display classic pathologic features or blastoid/pleomorphic morphology. (See <a class="local">'Morphology'</a> below.)</p><p>Lymphadenopathy may be relatively asymptomatic (eg, with smoldering MCL), or it can be more generalized and progressive. Involvement that is limited to a single lymph node region (ie, stage I) is rare. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extranodal disease</strong> – Extranodal sites are often involved by MCL, but isolated or predominant extranodal presentation is uncommon [<a href="#rid32">32</a>]. Examples of extranodal involvement by MCL include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal (GI) tract</strong> – GI tract involvement is very common, and it can involve any region of the GI tract. Patients may present with prominent GI symptoms, but others are asymptomatic [<a href="#rid32">32-34</a>]. In some instances, GI tract involvement takes the form of symptomatic intestinal polyps (so-called multiple lymphomatous polyposis)  (<a class="graphic graphic_picture graphicRef64338" href="/z/d/graphic/64338.html" rel="external">picture 1</a>) [<a href="#rid32">32,33,35,36</a>].</p><p></p><p class="bulletIndent2">A study of 31 cases of MCL with GI tract involvement reported the following distribution of disease: stomach (57 percent), duodenum (52 percent), jejunum/ileum (87 percent), colon (90 percent), and rectum (69 percent) [<a href="#rid35">35</a>]. Lymphomatous submucosal nodules producing polypoid lesions were found in both the small bowel and colon in 28 of the 31 cases. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other extranodal sites</strong> – MCL can involve any organ system, including the kidneys and, rarely, the central nervous system [<a href="#rid37">37,38</a>]. Extranodal involvement may cause significant symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoldering MCL</strong> – Patients with smoldering MCL are asymptomatic or have modest symptoms and have favorable prognosis, even without treatment [<a href="#rid39">39</a>]. These patients generally have lymph nodes &lt;3 cm and spleen &lt;20 cm, normal lactate dehydrogenase (LDH), leukocyte count &lt;30 x 10<sup>9</sup>/L, and Ki-67 index &lt;30 percent. They do not have blastoid/pleomorphic features or mutations of <em>TP53</em> or <em>NOTCH 1/2</em>.</p><p></p><p class="headingAnchor" id="H28003349"><span class="h2">Leukemic, non-nodal MCL</span><span class="headingEndMark"> — </span>This is a generally indolent form of MCL with a favorable prognosis. It commonly presents with lymphocytosis and splenomegaly. </p><p>Some cases of leukemic, non-nodal MCL exhibit marked lymphocytosis that can mimic prolymphocytic leukemia, acute leukemia, or chronic lymphocytic leukemia. In some cases, acquisition of <em>TP53</em> mutation can be associated with more aggressive behavior. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H2178381083"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Evaluation includes history and physical examination, laboratory studies, imaging, and biopsy.</p><p class="headingAnchor" id="H4245197185"><span class="h2">Clinical</span><span class="headingEndMark"> — </span>History and physical examination should evaluate the patient for lymphadenopathy, splenomegaly, gastrointestinal (GI) findings, and constitutional symptoms (unexplained fever, sweats, weight loss). The size of the liver and spleen should be documented, and examination should include Waldeyer's ring.</p><p class="headingAnchor" id="H2717615504"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Laboratory tests include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematology</strong> – Complete blood count (CBC) with differential count</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum chemistries</strong> – Comprehensive metabolic panel, including lactate dehydrogenase (LDH) and uric acid</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious diseases</strong> – Hepatitis B and HIV testing</p><p></p><p class="headingAnchor" id="H2018344140"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Positron emission tomography (PET)/computed tomography (CT) should be performed. If not, contrast-enhanced CT of neck, chest, abdomen, and pelvis should be obtained.</p><p>PET activity can vary in MCL and may be modest in cases with a low Ki-67 index.</p><p class="headingAnchor" id="H1406809663"><span class="h2">Clinical testing</span><span class="headingEndMark"> — </span>The following tests should be performed in selected patients.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>GI</strong> – Upper endoscopy and colonoscopy should be performed for patients with GI symptoms. Some experts obtain these studies in all patients with apparent early-stage MCL (ie, non-bulky stage I or stage II) to identify more extensive disease that might affect management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow</strong> – Bone marrow aspirate and biopsy should be obtained for patients with unexplained cytopenias. Bone marrow specimens can be useful to establish the diagnosis of MCL in cases that are not straightforward.</p><p></p><p class="bulletIndent1">Some experts perform bone marrow examination in all patients with early-stage MCL, when PET does not suggest bone marrow involvement; note that PET is not a sensitive method for detecting marrow involvement, especially in cases with a low Ki-67 index.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system (CNS)</strong> – Patients with unexplained neurologic abnormalities should have a lumbar puncture (LP; including cytology and molecular studies) and CNS imaging.</p><p></p><p class="bulletIndent1">We consider performing an LP for patients with blastoid or pleomorphic features, who have greater risk of CNS involvement.</p><p></p><p class="headingAnchor" id="H138239719"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Morphology, immunophenotyping, and genetic characterization are used to diagnose MCL.</p><p class="headingAnchor" id="H5"><span class="h2">Morphology</span><span class="headingEndMark"> — </span>MCL ordinarily displays a monomorphic pattern of small and intermediate size lymphoid cells with a diffuse or vaguely nodular pattern of growth. However, cellular features and growth patterns may vary from this typical appearance.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cellular features</strong> – There is a spectrum of morphologic variants of MCL, which includes classic MCL and blastoid or pleomorphic subtypes [<a href="#rid40">40</a>]. Recognition of patients with the blastoid/pleomorphic subtype of MCL has implications for management. (See  <a class="medical medical_review" href="/z/d/html/4719.html" rel="external">"Mantle cell lymphoma: Initial management", section on 'MCL with adverse features'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Classic MCL</strong> – Classic MCL  (<a class="graphic graphic_picture graphicRef77160" href="/z/d/graphic/77160.html" rel="external">picture 2</a>) is typically manifest as an infiltrate of small to medium size lymphocytes with scant cytoplasm, irregular or "notched" nuclear contours, dispersed or clumped chromatin, and inconspicuous nucleoli. The malignant cells can resemble centrocytes or small cleaved cells of follicular lymphoma; despite their small size and bland appearance, mitotic activity varies widely. Transformed tumor cells with basophilic cytoplasm (centroblast- or immunoblast-like cells) are rare or absent in classic MCL. Classic MCL often includes single interspersed epithelioid macrophages, which may be skewed towards an immunosuppressive "M2" state through cross-talk with MCL cells [<a href="#rid41">41</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blastoid/pleomorphic MCL</strong> – These MCL variants include larger cells or cells of variable size. In the blastoid variant  (<a class="graphic graphic_picture graphicRef86531" href="/z/d/graphic/86531.html" rel="external">picture 3</a>), the large cells have dispersed chromatin and a high mitotic rate that can resemble lymphoblastic lymphoma. In pleomorphic MCL, tumors are mixtures of small and large cells or atypical large cells with pale cytoplasm, oval irregular nuclei, prominent nucleoli, and a high mitotic rate (eg, 20 to 30 per 10 high power fields).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Non-nodal MCL</strong> – This subtype is characterized by the presence of small sized tumor cells in blood and the absence of nodal disease. Nuclear irregularity is less marked than in classic MCL, sometimes leading to confusion with chronic lymphocytic leukemia.</p><p></p><p class="bulletIndent1">Immunophenotype and genetic findings of MCL cells are described below. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth patterns</strong> – Growth patterns of MCL in lymph nodes are usually diffuse or vaguely nodular  (<a class="graphic graphic_picture graphicRef86533" href="/z/d/graphic/86533.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef86532" href="/z/d/graphic/86532.html" rel="external">picture 5</a>), or a combination of the two patterns. Some cases present with predominant involvement of mantle zones surrounding reactive B cell follicles. </p><p></p><p class="bulletIndent1">With in situ mantle cell neoplasm, characteristic MCL cells (with nuclear cyclin D1) are scattered in the mantle zones of otherwise normal-appearing lymph nodes. In situ mantle cell neoplasm is usually an incidental finding, but care must be taken to exclude minimal involvement by systemic MCL.</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Immunophenotype</span><span class="headingEndMark"> — </span>MCL cells are uniformly BCL2-positive and usually positive for CD5, negative (or weakly positive) for CD23, and negative for CD10 or BCL6 [<a href="#rid40">40</a>]. Nuclear cyclin D1 is expressed by &gt;95 percent of cases and SOX11 is expressed by &gt;90 percent of cases. Occasional cases are CD5–negative or CD23-positive. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nuclear cyclin D1</strong> – Nuclear staining for cyclin D1 is present in 95 percent of MCL cases, including those that are CD5-negative [<a href="#rid40">40</a>]. Cyclin D1 can be detected by immunohistochemical (IHC) staining in paraffin-embedded tissue sections, which distinguishes MCL from most other lymphomas. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">Cases that lack the t(11;14) may overexpress cyclin D1 by other mechanisms, such as <em>CCND1</em> point mutations that increase its expression [<a href="#rid42">42</a>]. Conversely, in rare instances, cyclin D1 staining is absent in MCL that have the t(11;14) and high levels of <em>CCND1</em> expression, due to mutations of the <em>CCND1</em> coding sequence that prevent recognition by commonly used anti-cyclin D1 antibodies [<a href="#rid43">43</a>]. </p><p></p><p class="bulletIndent1">Cyclin D2 or cyclin D3 are overexpressed in rare cases of MCL that are cyclin D1-negative and lack t(11;14) [<a href="#rid44">44-47</a>]. Morphology, immunophenotype, gene expression profiles, and clinical characteristics of cyclin D1-negative MCL are similar to those of cyclin D1-positive MCL [<a href="#rid45">45,46,48,49</a>]. Cyclins D1, D2, and D3 are highly homologous and functionally interchangeable. However, IHC for cyclin D2 or cyclin D3 is not helpful for diagnosing cyclin D1-negative MCL, as these proteins are also expressed in other B cell malignancies. Recognition that cyclin D1-negative MCL usually expresses SOX11 (which is only rarely expressed by other lymphoid neoplasms) provides a generally reliable means to recognize these rare variants [<a href="#rid50">50</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SOX11</strong> – SOX11, a member of the SRY-related HMG family of transcription factors, is expressed in &gt;90 percent of cases, including cyclin D1-negative cases and blastoid variants [<a href="#rid51">51-53</a>]. SOX11 is a useful marker for MCL, particularly in rare cyclin D1-negative cases. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphoid antigens</strong> – MCL cells are typically positive for CD5, pan-B cell antigens (eg, CD19, CD20, FMC7), and CD43 (leukosialin), and generally do not express CD23 [<a href="#rid40">40</a>]. MCL cells express high levels of surface IgM and IgD. For unknown reasons, there is marked skewing (up to 80 percent of cases) towards lambda immunoglobulin light chain expression. Rare cases of MCL are CD5–negative or CD23-positive. </p><p></p><p class="bulletIndent1">In lymphomatous polyposis (GI tract involvement), tumor cells express alpha-4/beta-7 integrin (CD49d), which is normally involved in lymphocyte homing to high endothelial venules in gut-associated lymphoid tissues [<a href="#rid54">54,55</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>p53</strong> – Accumulation of the tumor suppressor p53 (encoded by <em>TP53</em>) in tumor cells is a surrogate for the presence of <em>TP53</em> mutations and is more often found in the blastoid variant and in highly proliferative tumors. Accordingly, IHC detection of p53 in tumor cells is associated with an adverse prognosis [<a href="#rid56">56-58</a>]. </p><p></p><p class="bulletIndent1">IHC staining for p53 in formalin-fixed paraffin-embedded sections generally correlates well with <em>TP53</em> mutations, as these mutations stabilize the<em> </em>p53 protein, which accumulates in tumor cells. Some experts favor the use of DNA sequencing to detect cases with mutated <em>TP53</em> that may not exhibit p53 by IHC staining [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1">In one study, IHC was 82 percent sensitive and 100 percent specific for <em>TP53</em> mutations [<a href="#rid57">57</a>]. In another study,<em> TP53</em> abnormalities were found in 21 percent of 255 patients with MCL and were associated with a threefold increased risk of death [<a href="#rid60">60</a>]; in this study, IHC failed to detect approximately 5 percent of cases with mutated <em>TP53</em> [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Genetic features</span><span class="headingEndMark"> — </span>The t(11;14)(q13;q32), which rearranges the <em>CCND1</em> locus (encoding cyclin D1) and immunoglobulin heavy chain (<em>IgH</em>) locus  (<a class="graphic graphic_picture graphicRef58342" href="/z/d/graphic/58342.html" rel="external">picture 6</a>), is present in &gt;95 percent of cases of MCL. Cyclin D1 is considered the primary genetic driver of MCL. </p><p>The t(11;14) deregulates expression of <em>CCND1</em> mRNA and cyclin D1 protein [<a href="#rid40">40</a>]. The translocation appears to be mediated by recombinase-activating genes (RAG) and activation-induced cytidine deaminase (AID) [<a href="#rid61">61</a>]. The t(11;14) rearrangement is not specific for MCL, as it occurs in some cases of multiple myeloma and, rarely, in other lymphoid malignancies [<a href="#rid62">62</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chromosomal changes</strong> – In addition to the t(11;14), MCL cells often have non-random secondary chromosomal abnormalities, including [<a href="#rid15">15,63,64</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gains</strong> – Gain of 3q26 (31 to 50 percent of cases), 7p21 (16 to 34 percent), and 8q24 (including <em>MYC</em>; 16 to 36 percent)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Losses</strong> – Loss of 1p13 (29 to 52 percent), 6p23-27 (23 to 38 percent), 9p21 (<em>CDKN2A</em>, which encodes p16INK4a and p14ARF; 18 to 31 percent), 11q22-23 (<em>ATM</em>; 21 to 59 percent), 13q11-13 (22 to 55 percent), 13q14-34 (43 to 51 percent), and 17p13 (<em>TP53</em>; 21 to 45 percent) </p><p></p><p class="bulletIndent1">In 60 cases of the blastoid variant of MCL, 80 percent had at least one cytogenetic abnormality in addition to t(11;14) [<a href="#rid65">65</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular changes</strong> – Most mutations in MCL affect cell cycle regulators, DNA damage response pathways, cell survival pathways, and other mechanisms [<a href="#rid26">26,66-70</a>], as described above. (See <a class="local">'Pathobiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cyclins</strong> – In addition to the t(11;14), <em>CCND1</em> mutations are seen in one-third of cases [<a href="#rid67">67,68</a>]. Point mutations and deletions that affect the 3' untranslated region of <em>CCND1</em> can generate a truncated mRNA, which increases mRNA levels and is associated with poor clinical outcomes [<a href="#rid42">42,66,71,72</a>]. Occasionally, the immunoglobulin light chain loci, <em>IGK</em> or <em>IGL</em>, serve as the <em>CCND1</em> translocation partner; in some cases that strongly express cyclin D1 without <em>CCND1</em> rearrangement by fluorescence in situ hybridization (FISH), cryptic rearrangements of <em>IGK</em> or <em>IGL</em> enhancers with <em>CCND1</em> are found [<a href="#rid73">73-75</a>]. </p><p></p><p class="bulletIndent2">In rare cases of MCL with cyclin D2 or cyclin D3 overexpression, <em>CCND2, CCND3, or CCNE</em> rearrangements have been identified [<a href="#rid44">44,48</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other mutations</strong> – Other mutated genes in MCL include: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>SOX11</strong> – Expressed in &gt;90 percent of cases of MCL [<a href="#rid76">76-78</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>TP53</em></strong> – Patients with <em>TP53</em> mutation or deletion generally have poor clinical outcomes, including shortened survival and poor response to chemoimmunotherapy [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Others</strong> – Other aberrant genes include gain-of-function mutations<em> of NOTCH1 or NOTCH2</em>, DNA damage response gen<em>es (ATM</em>,<em> TP53</em>)<em>,</em> apoptosis regulators (<em>BIRC3</em>,<em> TLR2</em>)<em>,</em> and chromatin modifiers (<em>WHSC1, MLL2, MEF2B</em>) [<a href="#rid66">66,67,79</a>]. A study of 134 cases of MCL also reported mutations of <em>LRP1B, PCLO, RYR2, PCDH10, OBSCN, TACC2, FAT3, LRP2, SVEP1, ZFHX4, MPDZ, DCDC1, IKBKB</em>, <em>and ARID1A</em> [<a href="#rid80">80</a>]. </p><p></p><p class="headingAnchor" id="H9"><span class="h1">DIAGNOSIS AND CLASSIFICATION</span><span class="headingEndMark"> — </span>MCL and other lymphomas may be suspected in individuals with lymphadenopathy, splenomegaly, circulating aberrant lymphoid cells, and/or unexplained gastrointestinal (GI) symptoms.</p><p>The International Consensus Classification (ICC) [<a href="#rid30">30</a>] and the World Health Organization 5<sup>th</sup> edition (WHO5) [<a href="#rid31">31</a>] use similar criteria to diagnose and classify MCL. Further description of the ICC and WHO5 systems is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Lymphoid neoplasms'</a>.)</p><p class="headingAnchor" id="H3897759624"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Diagnosis of MCL requires a tissue specimen, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morphology and immunophenotype</strong> – Microscopy and immunophenotyping indicate a B cell lymphoma consistent with MCL: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microscopy</strong> – Tissues involved by classic MCL are generally effaced by a monomorphous infiltrate of small to intermediate size lymphocytes with irregular nuclei and a diffuse or vaguely nodular pattern of growth. The blastoid/pleomorphic subtype may have larger or more variable cell size and other features, described above. (See <a class="local">'Morphology'</a> above.)</p><p></p><p class="bulletIndent2">Non-nodal MCL usually presents with peripheral blood lymphocytosis and bone marrow involvement. Nuclear irregularity is often less prominent than in classic MCL, which may lead to confusion with chronic lymphocytic leukemia.</p><p></p><p class="bulletIndent2">In rare cases of in situ mantle cell neoplasm, characteristic cyclin D1-positive tumor cells are scattered in mantle zones of otherwise normal-appearing lymph nodes. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunophenotype</strong> – In classic MCL, involved nodal and extranodal tissues reveal tumor cells that express nuclear cyclin D1 by immunohistochemistry and are typically CD5-positive and CD23–negative. SOX11 staining is helpful in the cases of classic MCL that are negative for t(11;14) and fail to express cyclin D1. </p><p></p><p>Non-nodal MCL is usually characterized by flow cytometry (rather than immunohistochemistry) of blood or marrow, while <em>CCND1</em> rearrangement is more often recognized directly by karyotyping or fluorescence in situ hybridization (FISH; rather than by immunostaining for cyclin D1). SOX11 is often weakly expressed or negative and this variant is also more likely to be CD5-negative and CD23-positive. The Ki-67 proliferation index is usually less than 10 percent.</p><p class="bulletIndent2">Other immunophenotypic features of MCL cells are discussed above. (See <a class="local">'Immunophenotype'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – The t(11;14) rearrangement is detected by karyotype (chromosomal banding) or FISH in nearly all cases of MCL. </p><p></p><p class="bulletIndent1">Rare cases of cyclin D1-positive MCL without detectable t(11;14), and cyclin D1-negative cases that express cyclin D2 or cyclin D3 are described above. (See <a class="local">'Genetic features'</a> above.)</p><p></p><p class="headingAnchor" id="H2549323011"><span class="h2">Classification</span><span class="headingEndMark"> — </span>Both ICC and WHO5 classify cases of MCL as follows [<a href="#rid30">30,31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic</strong> <strong>MCL</strong> – Conventional cyclin D1-positive MCL is associated with the <em>IGH::CCND1</em> fusion and t(11;14) in ≥95 percent of cases [<a href="#rid81">81,82</a>]. Rare cases with alternative genetic findings are described above. (See <a class="local">'Genetic features'</a> above.)</p><p></p><p class="bulletIndent1">We evaluate cases of classic MCL for high-risk features that are associated with adverse prognosis, including cytomorphology (pleomorphic or blastoid appearance), high Ki-67 proliferative index, and p53 expression/<em>TP53</em> mutation [<a href="#rid28">28,56,83-85</a>]. (See <a class="local">'Morphology'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-nodal MCL</strong> – Recognition of this more favorable prognosis subtype relies on a combination of clinical and pathological characteristics. Non-nodal MCL is generally asymptomatic and typically involves blood, bone marrow, and spleen, with little or no lymphadenopathy. GI involvement may occasionally be seen. Non-nodal MCL typically shows little (&lt;10 percent of cells) or no SOX11 expression, and low Ki-67 index. It is more likely than classic MCL to express CD23 and CD200 and to lack CD5 expression [<a href="#rid13">13,86-93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>In situ mantle cell neoplasm</strong> – In situ mantle cell neoplasm is a rare and often incidental finding manifest as colonization by cyclin D1-positive B cells of the inner mantle zones of follicles in otherwise normal-appearing lymph nodes [<a href="#rid94">94</a>]. Some patients with suspected in situ mantle cell neoplasm will prove to have disseminated MCL on further work-up [<a href="#rid95">95</a>]. In situ mantle cell neoplasm is sometimes seen in association with other B cell lymphomas. </p><p></p><p class="headingAnchor" id="H10"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>MCL is typically characterized by an infiltrate of small to intermediate size B lymphocytes with irregular nuclei and a diffuse or vaguely nodular pattern of growth; the t(11;14) and nuclear cyclin D1 is seen in most cases. MCL is distinguished from other lymphomas in the differential diagnosis by morphology, immunophenotype, and genomic features.</p><p class="headingAnchor" id="H11"><span class="h2">Chronic lymphocytic leukemia</span><span class="headingEndMark"> — </span>Both MCL and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are neoplasms of small to medium-sized lymphoid cells that can present with lymphadenopathy, splenomegaly, and constitutional symptoms. They have similar immunophenotypes, but while CLL is positive for CD20 (usually dimly), CD5, CD23, and CD200, MCL is positive for CD20 (usually brightly) and CD5 and negative for CD23 and CD200. Non-nodal MCL may more closely resemble CLL phenotypically but can be reliably distinguished by detection of the t(11;14) and overexpression of cyclin D1.</p><p>Immunohistochemistry for cyclin D1 is helpful for excluding CLL. Other discriminating markers include SOX11 (positive in most MCL) and LEF1 (frequently positive in CLL). Demonstration of the t(11;14) by fluorescence in situ hybridization (FISH) also distinguishes MCL from CLL/SLL [<a href="#rid96">96</a>]; instead, CLL cells may have del(11q), trisomy 12, del(13q), or del(17p). (See  <a class="medical medical_review" href="/z/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Follicular lymphoma</span><span class="headingEndMark"> — </span>Some cases of MCL have a predominantly nodular growth pattern that resembles follicular lymphoma; conversely, an unusual variant of follicular lymphoma with a predominantly diffuse growth pattern that usually presents in inguinal lymph nodes can mimic the histologic appearance of MCL [<a href="#rid97">97</a>]. Both MCL and follicular lymphoma can present with gastrointestinal (GI) symptoms from lymphomatous polyposis. In contrast to follicular lymphoma, MCL cells are usually positive for CD5, CD43, and cyclin D1 and lack the characteristic genetic finding in follicular lymphoma, the t(14;18). (See  <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Marginal zone lymphoma (nodal or extranodal)</span><span class="headingEndMark"> — </span>Both extranodal marginal zone lymphoma (MZL) and MCL can involve the GI tract and are neoplasms of small to medium-sized B lymphocytes. MCL cells generally express CD5 and cyclin D1, while extranodal MZL does not. In addition, MZL often contains monocytoid B cells and shows plasmacytic differentiation, which are not features of MCL. (See  <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"</a>.)</p><p class="headingAnchor" id="H2053953200"><span class="h2">Large B cell lymphoma</span><span class="headingEndMark"> — </span>Malignant cells of large B cell lymphoma are generally larger than the tumor cells of MCL, but blastoid/pleomorphic MCL may include larger cells. MCL is distinguished from large B cell lymphoma by the characteristic immunophenotype of MCL and the t(11;14) or <em>IGH::CCND1</em> rearrangement. However, <em>CCND1</em> rearrangement has been found in some large B cell lymphomas, sometimes in association with <em>MYC</em>, and <em>BCL2</em> or <em>BCL6</em> translocations. In ambiguous cases, a diagnosis of large B cell lymphoma is favored by lack of CD5 and SOX11 expression and/or detection of mutations that are uncommon in MCL [<a href="#rid98">98</a>]. (See  <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma"</a>.)</p><p class="headingAnchor" id="H16168351"><span class="h2">Lymphoblastic lymphoma</span><span class="headingEndMark"> — </span>The blastoid variant of MCL, with intermediate size cells with dispersed chromatin and high mitotic rate, can resemble lymphoblastic lymphoma, which can be of B or T cell origin. </p><p>Blastoid MCL is readily distinguished from lymphoblastic lymphoma by immunohistochemistry. Blastoid MCL expresses cyclin D1 and mature B cell markers, whereas B lymphoblastic lymphomas lack surface immunoglobulin and express TdT, while T lymphoblastic lymphomas express TdT, lack B cell markers, and express additional T cell markers besides CD5. (See  <a class="medical medical_review" href="/z/d/html/4686.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/15773.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma"</a>.) </p><p class="headingAnchor" id="H2330318930"><span class="h2">Plasma cell neoplasm with CCND1 rearrangement</span><span class="headingEndMark"> — </span>Plasma cell neoplasms (eg, multiple myeloma) can also have the t(11;14) with <em>IGH::CCND1</em> rearrangement; notably, these tumors are often composed of small plasma cells that express B cell markers such as CD20, leading to possible confusion with MCL. The distinction is typically made by recognizing plasmacytoid differentiation; the failure to express MCL markers (eg, CD5 and SOX11); and the presence of typical clinical features of plasma cell neoplasms, such as monoclonal gammopathy, hypercalcemia, and renal dysfunction.</p><p class="headingAnchor" id="H14"><span class="h1">PROGNOSTIC FEATURES</span><span class="headingEndMark"> — </span>Prognosis of MCL is affected by the clinical presentation, disease stage, and pathologic features. Prognosis of patients with MCL is variable, but it can be estimated using a clinical prognostic model. </p><p class="headingAnchor" id="H1823698288"><span class="h2">Pathologic features</span><span class="headingEndMark"> — </span>Histologic and genetic features of MCL tumor that are associated with adverse outcomes include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blastoid/pleomorphic histology</strong> – The blastoid/pleomorphic variant of MCL is associated with adverse outcomes and poor response to chemoimmunotherapy [<a href="#rid99">99-104</a>]. Pathologic features of blastoid/pleomorphic MCL are described above. (See <a class="local">'Diagnosis and classification'</a> above.)</p><p></p><p class="bulletIndent1">In one series of 52 patients with MCL, blastoid transformation occurred in one-third of cases, with a median survival time following transformation of four months [<a href="#rid105">105</a>]. Nearly all (16 or 18 patients) had systemic involvement with circulating blastoid cells at the time of transformation. Leukocytosis, elevated serum LDH level, and high proliferative activity (as assessed by Ki-67 staining) were associated with increased risk of transformation. In separate studies, age &gt;60 and an increased mitotic index [<a href="#rid106">106</a>] or increased Ki-67 staining [<a href="#rid83">83,107,108</a>] were associated with significantly worse overall survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Patients whose MCL has mutant <em>TP53</em> or high p53 expression have reduced survival and a higher rate of relapse [<a href="#rid28">28</a>]. In a cohort of 365 patients with MCL, high p53 expression by immunohistochemistry was a strong predictor of inferior overall survival (OS) and earlier time to treatment failure (TTF); this association was independent of MIPI score and Ki-67 index in multivariable analysis [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1">Other genetic findings are associated with inferior outcomes, including unmutated <em>IGHV</em>; mutated <em>CDKN2A</em>, <em>NOTCH1</em>, or <em>NOTCH2</em>; <em>MYC</em> overexpression; and genomic complexity [<a href="#rid20">20,87-89</a>]. </p><p></p><p class="headingAnchor" id="H779688691"><span class="h2">Mantle cell lymphoma international prognostic index (MIPI)</span><span class="headingEndMark"> — </span>The mantle cell lymphoma international prognostic index (MIPI) (<a class="calc calc_professional" href="/z/d/html/83044.html" rel="external">calculator 1</a>)  (<a class="graphic graphic_table graphicRef86535" href="/z/d/graphic/86535.html" rel="external">table 1</a>) can be used to estimate prognosis in patients with MCL [<a href="#rid109">109,110</a>].</p><p>The MIPI and a simplified MIPI (performance status, age, increased serum lactate dehydrogenase [LDH], and leukocyte count) were created using data from 455 patients with advanced-stage MCL who enrolled in clinical trials between 1996 and 2004 [<a href="#rid109">109</a>]. Patients were stratified into three risk groups (low, intermediate, and high) with distinct outcomes (median OS not reached, 58 months, and 37 months, respectively) and five-year OS (60, 35, and 20 percent)  (<a class="graphic graphic_table graphicRef86535" href="/z/d/graphic/86535.html" rel="external">table 1</a>). The prognostic value of the MIPI was confirmed in a separate cohort of 958 patients with MCL treated on prospective trials (2004 to 2010); in this analysis, estimated five-year OS were 83, 63, and 34 percent in the low, intermediate, and high groups, respectively [<a href="#rid111">111</a>].</p><p>Modifications of a simplified MIPI score have incorporated Ki-67 expression (MIPI-B) and <em>miR-18b</em> expression (MIPI-B-miR). These modified MIPI scores were effective for estimating prognosis in trials with long-term follow-up [<a href="#rid111">111-113</a>].</p><p>In a study of 158 patients with MCL who received intensive induction chemoimmunotherapy followed by autologous hematopoietic cell transplantation, MIPI was superior to the International Prognostic Index (IPI) for predicting survival [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H3605824900"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117911.html" rel="external">"Society guideline links: Lymphoma diagnosis and staging"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122016.html" rel="external">"Society guideline links: Management of mantle cell lymphoma"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Mantle cell lymphoma (MCL) is a mature B cell non-Hodgkin lymphoma (NHL) with a variable natural history that can involve lymph nodes or extranodal sites, including blood, bone marrow, or gastrointestinal (GI) tract. Among lymphomas, MCL is distinguished by nuclear expression of cyclin D1 and t(11;14).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – MCL accounts for approximately 7 percent of NHL, with a strong male predominance and median 68 years at presentation. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathobiology</strong> – Increased proliferation, blunted DNA damage response, and impaired apoptosis are seen  (<a class="graphic graphic_figure graphicRef73115" href="/z/d/graphic/73115.html" rel="external">figure 1</a>). Nearly all cases express cyclin D1, due to the t(11;14), which juxtaposes <em>CCND1</em> and <em>IGH</em> (immunoglobulin heavy chain gene) and acts as the genetic driver of most cases. (See <a class="local">'Pathobiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Most patients have lymphadenopathy and splenomegaly; some have constitutional symptoms and/or GI or other extranodal symptoms. The two major subtypes, classic MCL and non-nodal MCL, present differently. Most patients have advanced-stage disease at diagnosis. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology </strong>– Characteristic features include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Morphology</strong> – Small to intermediate size lymphoid cells with irregular, notched nuclei in a diffuse or vaguely nodular pattern  (<a class="graphic graphic_picture graphicRef77160" href="/z/d/graphic/77160.html" rel="external">picture 2</a>). However, morphology may vary, and the blastoid/pleomorphic subtype has larger, more proliferative cells. (See <a class="local">'Morphology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunophenotype</strong> – Nuclear cyclin D1 is nearly universal. Most cells are positive for CD5, BCL2, and SOX11, and negative for CD23. However, occasional cases (particularly non-nodal MCL) are CD5–negative or CD23-positive. (See <a class="local">'Immunophenotype'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Genetic features</strong> – Nearly all cases demonstrate the t(11;14), which rearranges <em>CCND1</em> and immunoglobulin regulatory elements. Some cases overexpress cyclin D1 due to <em>CCND1</em> mutation or variant rearrangements, while rare variants express cyclins D2 or D3. (See <a class="local">'Genetic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Requires a tissue biopsy that demonstrates (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Morphology</strong> – Consistent with MCL, described above. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunophenotype</strong> – Typically positive for nuclear cyclin D1 and CD5, BCL2, and SOX11, and negative for CD23. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Genetics</strong> – The t(11;14)(q13;q32) and/or <em>CCND1::IGH</em> rearrangement; rare cases have variant molecular events. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – We classify MCL as (see <a class="local">'Classification'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Classic</strong> <strong>MCL</strong> – Cyclin D1-positive MCL with t(11;14) and/or <em>IGH::CCND1</em>. This includes cases with high-risk features/adverse prognosis (eg, blastoid/pleomorphic morphology, high Ki-67 index, p53 expression/mutated <em>TP53</em>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Non-nodal </strong>– A more favorable prognostic group recognized by clinical and pathological characteristics, including asymptomatic presentation with splenomegaly and little/no lymphadenopathy, low/negative SOX11 expression, low Ki-67 index, CD23 and CD200 expression, and often lacks CD5 expression. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>In situ mantle cell lymphoma</strong> – Rare and typically incidental finding of colonization by cyclin D1-positive cells in mantle zones of otherwise normal-appearing lymph node follicles.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Other lymphomas with small or intermediate size tumor cells, including chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, large B cell lymphoma, or lymphoblastic lymphoma, which are distinguished from MCL by the characteristic immunophenotype and/or genetic findings of MCL. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic features</strong> – Prognosis is associated with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pathology</strong> – Blastoid/pleomorphic morphology and <em>TP53</em> mutations are associated with adverse outcomes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prognostic index</strong> – Mantle cell lymphoma International Prognostic Index (MIPI) (<a class="calc calc_professional" href="/z/d/html/83044.html" rel="external">calculator 1</a>)  (<a class="graphic graphic_table graphicRef86535" href="/z/d/graphic/86535.html" rel="external">table 1</a>). (See <a class="local">'Prognostic features'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016; 66:443.</a></li><li><a class="nounderline abstract_t">Armitage JO, Longo DL. Mantle-Cell Lymphoma. N Engl J Med 2022; 386:2495.</a></li><li><a class="nounderline abstract_t">Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.</a></li><li><a class="nounderline abstract_t">Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.</a></li><li><a class="nounderline abstract_t">Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008; 113:791.</a></li><li><a class="nounderline abstract_t">Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.</a></li><li><a class="nounderline abstract_t">Raffeld M, Jaffe ES. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 1991; 78:259.</a></li><li><a class="nounderline abstract_t">Quintanilla-Martinez L, Davies-Hill T, Fend F, et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 2003; 101:3181.</a></li><li><a class="nounderline abstract_t">Jares P, Campo E, Pinyol M, et al. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol 1996; 148:1591.</a></li><li><a class="nounderline abstract_t">Walsh SH, Thorsélius M, Johnson A, et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 2003; 101:4047.</a></li><li><a class="nounderline abstract_t">Camacho FI, Algara P, Rodríguez A, et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 2003; 101:4042.</a></li><li><a class="nounderline abstract_t">Kienle D, Kröber A, Katzenberger T, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003; 102:3003.</a></li><li><a class="nounderline abstract_t">Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101:4975.</a></li><li><a class="nounderline abstract_t">Thelander EF, Walsh SH, Thorsélius M, et al. Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes. Mod Pathol 2005; 18:331.</a></li><li><a class="nounderline abstract_t">Seto M, Yamamoto K, Iida S, et al. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene 1992; 7:1401.</a></li><li><a class="nounderline abstract_t">Gelebart P, Anand M, Armanious H, et al. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 2008; 112:5171.</a></li><li><a class="nounderline abstract_t">Ryan RJH, Petrovic J, Rausch DM, et al. A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell Rep 2017; 21:784.</a></li><li><a class="nounderline abstract_t">Dai B, Grau M, Juilland M, et al. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood 2017; 129:333.</a></li><li><a class="nounderline abstract_t">Hofmann WK, de Vos S, Tsukasaki K, et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001; 98:787.</a></li><li><a class="nounderline abstract_t">Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol 2019; 94:710.</a></li><li><a class="nounderline abstract_t">Menendez P, Vargas A, Bueno C, et al. Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia 2004; 18:491.</a></li><li><a class="nounderline abstract_t">Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9:59.</a></li><li><a class="nounderline abstract_t">Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009; 139:573.</a></li><li><a class="nounderline abstract_t">Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006; 108:1668.</a></li><li><a class="nounderline abstract_t">Pham LV, Tamayo AT, Yoshimura LC, et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171:88.</a></li><li><a class="nounderline abstract_t">Rahal R, Frick M, Romero R, et al. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nat Med 2014; 20:87.</a></li><li><a class="nounderline abstract_t">Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507.</a></li><li><a class="nounderline abstract_t">Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 2017; 130:1903.</a></li><li><a class="nounderline abstract_t">Pararajalingam P, Coyle KM, Arthur SE, et al. Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood 2020; 136:572.</a></li><li><a class="nounderline abstract_t">Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.</a></li><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li><a class="nounderline abstract_t">Morello L, Rattotti S, Giordano L, et al. Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. Hemasphere 2020; 4:e302.</a></li><li><a class="nounderline abstract_t">Romaguera JE, Medeiros LJ, Hagemeister FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003; 97:586.</a></li><li><a class="nounderline abstract_t">Salar A, Juanpere N, Bellosillo B, et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol 2006; 30:1274.</a></li><li><a class="nounderline abstract_t">Ruskoné-Fourmestraux A, Delmer A, Lavergne A, et al. Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D'étude des Lymphomes Digestifs. Gastroenterology 1997; 112:7.</a></li><li><a class="nounderline abstract_t">O'Briain DS, Kennedy MJ, Daly PA, et al. Multiple lymphomatous polyposis of the gastrointestinal tract. A clinicopathologically distinctive form of non-Hodgkin's lymphoma of B-cell centrocytic type. Am J Surg Pathol 1989; 13:691.</a></li><li><a class="nounderline abstract_t">Gill S, Herbert KE, Prince HM, et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol 2009; 147:83.</a></li><li><a class="nounderline abstract_t">Cheah CY, George A, Giné E, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol 2013; 24:2119.</a></li><li><a class="nounderline abstract_t">Ye H, Desai A, Zeng D, et al. Smoldering mantle cell lymphoma. J Exp Clin Cancer Res 2017; 36:185.</a></li><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Le K, Sun J, Khawaja H, et al. Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis. Blood Adv 2021; 5:2863.</a></li><li><a class="nounderline abstract_t">Wiestner A, Tehrani M, Chiorazzi M, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 2007; 109:4599.</a></li><li><a class="nounderline abstract_t">Iaccarino I, Afify L, Aukema SM, et al. t(11;14)-positive mantle cell lymphomas lacking cyclin D1 (CCND1) immunostaining because of a CCND1 mutation or exclusive expression of the CCND1b isoform. Haematologica 2018; 103:e432.</a></li><li><a class="nounderline abstract_t">Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008; 111:5683.</a></li><li><a class="nounderline abstract_t">Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106:4315.</a></li><li><a class="nounderline abstract_t">Iqbal J, Shen Y, Liu Y, et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 2012; 119:4939.</a></li><li><a class="nounderline abstract_t">Hartmann EM, Campo E, Wright G, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010; 116:953.</a></li><li><a class="nounderline abstract_t">Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood 2013; 121:1394.</a></li><li><a class="nounderline abstract_t">Nagy B, Lundán T, Larramendy ML, et al. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 2003; 120:434.</a></li><li class="breakAll">World health organization classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC, Lyon 2017.</li><li><a class="nounderline abstract_t">Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009; 94:1555.</a></li><li><a class="nounderline abstract_t">Nakashima MO, Durkin L, Bodo J, et al. Utility and diagnostic pitfalls of SOX11 monoclonal antibodies in mantle cell lymphoma and other lymphoproliferative disorders. Appl Immunohistochem Mol Morphol 2014; 22:720.</a></li><li><a class="nounderline abstract_t">Soldini D, Valera A, Solé C, et al. Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma. Am J Surg Pathol 2014; 38:86.</a></li><li><a class="nounderline abstract_t">Mynster T, Hultberg B, Bülow S. Multiple lymphomatous polyposis of the colon and rectum. Report of a case and review of the literature. Scand J Gastroenterol 1994; 29:545.</a></li><li><a class="nounderline abstract_t">Hashimoto Y, Nakamura N, Kuze T, et al. Multiple lymphomatous polyposis of the gastrointestinal tract is a heterogenous group that includes mantle cell lymphoma and follicular lymphoma: analysis of somatic mutation of immunoglobulin heavy chain gene variable region. Hum Pathol 1999; 30:581.</a></li><li><a class="nounderline abstract_t">Aukema SM, Hoster E, Rosenwald A, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood 2018; 131:417.</a></li><li><a class="nounderline abstract_t">Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol 2018; 5:e109.</a></li><li><a class="nounderline abstract_t">Nordström L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study. Br J Haematol 2014; 166:98.</a></li><li><a class="nounderline abstract_t">Lew TE, Minson A, Dickinson M, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol 2023; 10:e142.</a></li><li><a class="nounderline abstract_t">Rodrigues JM, Hassan M, Freiburghaus C, et al. p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma. Br J Haematol 2020; 191:796.</a></li><li><a class="nounderline abstract_t">Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362:1417.</a></li><li><a class="nounderline abstract_t">Panayiotidis P, Kotsi P. Genetics of small lymphocyte disorders. Semin Hematol 1999; 36:171.</a></li><li><a class="nounderline abstract_t">Rubio-Moscardo F, Climent J, Siebert R, et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005; 105:4445.</a></li><li><a class="nounderline abstract_t">Beà S, Ribas M, Hernández JM, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999; 93:4365.</a></li><li><a class="nounderline abstract_t">Parry-Jones N, Matutes E, Morilla R, et al. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH. Br J Haematol 2007; 137:117.</a></li><li><a class="nounderline abstract_t">Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012; 119:1963.</a></li><li><a class="nounderline abstract_t">Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 2013; 110:18250.</a></li><li><a class="nounderline abstract_t">Fernàndez V, Hartmann E, Ott G, et al. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005; 23:6364.</a></li><li><a class="nounderline abstract_t">Meissner B, Kridel R, Lim RS, et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 2013; 121:3161.</a></li><li><a class="nounderline abstract_t">Zhang J, Jima D, Moffitt AB, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood 2014; 123:2988.</a></li><li><a class="nounderline abstract_t">Chen RW, Bemis LT, Amato CM, et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 2008; 112:822.</a></li><li><a class="nounderline abstract_t">Shakir R, Ngo N, Naresh KN. Correlation of cyclin D1 transcript levels, transcript type and protein expression with proliferation and histology among mantle cell lymphoma. J Clin Pathol 2008; 61:920.</a></li><li><a class="nounderline abstract_t">Royo C, Salaverria I, Hartmann EM, et al. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 2011; 21:322.</a></li><li><a class="nounderline abstract_t">Fuster C, Martín-Garcia D, Balagué O, et al. Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma. Haematologica 2020; 105:e408.</a></li><li><a class="nounderline abstract_t">Peterson JF, Baughn LB, Ketterling RP, et al. Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies. Blood Adv 2019; 3:1298.</a></li><li><a class="nounderline abstract_t">Vegliante MC, Palomero J, Pérez-Galán P, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 2013; 121:2175.</a></li><li><a class="nounderline abstract_t">Ferrando AA. SOX11 is a mantle cell lymphoma oncogene. Blood 2013; 121:2169.</a></li><li><a class="nounderline abstract_t">Raphael M, Gentilhomme O, Tulliez M, et al. Histopathologic features of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors. Arch Pathol Lab Med 1991; 115:15.</a></li><li><a class="nounderline abstract_t">Leshchenko VV, Kuo PY, Shaknovich R, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010; 116:1025.</a></li><li><a class="nounderline abstract_t">Yi S, Yan Y, Jin M, et al. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest 2022; 132.</a></li><li><a class="nounderline abstract_t">Li JY, Gaillard F, Moreau A, et al. Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol 1999; 154:1449.</a></li><li><a class="nounderline abstract_t">Vandenberghe E, De Wolf-Peeters C, van den Oord J, et al. Translocation (11;14): a cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage. J Pathol 1991; 163:13.</a></li><li><a class="nounderline abstract_t">Hoster E, Rosenwald A, Berger F, et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol 2016; 34:1386.</a></li><li><a class="nounderline abstract_t">Abrisqueta P, Scott DW, Slack GW, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol 2017; 28:2489.</a></li><li><a class="nounderline abstract_t">Klapper W, Hoster E, Determann O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009; 2:103.</a></li><li><a class="nounderline abstract_t">Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012; 72:5307.</a></li><li><a class="nounderline abstract_t">Nadeu F, Martin-Garcia D, Clot G, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood 2020; 136:1419.</a></li><li><a class="nounderline abstract_t">Clot G, Jares P, Giné E, et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood 2018; 132:413.</a></li><li><a class="nounderline abstract_t">Xu J, Wang L, Li J, et al. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients. Am J Surg Pathol 2019; 43:710.</a></li><li><a class="nounderline abstract_t">Croci GA, Hoster E, Beà S, et al. Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11. Virchows Arch 2020; 477:259.</a></li><li><a class="nounderline abstract_t">Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 2012; 26:1895.</a></li><li><a class="nounderline abstract_t">Pouliou E, Xochelli A, Kanellis G, et al. Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence. Am J Pathol 2017; 187:1454.</a></li><li><a class="nounderline abstract_t">Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 2011; 118:3088.</a></li><li><a class="nounderline abstract_t">Oishi N, Montes-Moreno S, Feldman AL. In situ neoplasia in lymph node pathology. Semin Diagn Pathol 2018; 35:76.</a></li><li><a class="nounderline abstract_t">Carvajal-Cuenca A, Sua LF, Silva NM, et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 2012; 97:270.</a></li><li><a class="nounderline abstract_t">Barna G, Reiniger L, Tátrai P, et al. The cut-off levels of CD23 expression in the differential diagnosis of MCL and CLL. Hematol Oncol 2008; 26:167.</a></li><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a class="nounderline abstract_t">Cheng J, Hashem MA, Barabé F, et al. CCND1 Genomic Rearrangement as a Secondary Event in High Grade B-Cell Lymphoma. Hemasphere 2021; 5:e505.</a></li><li><a class="nounderline abstract_t">A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909.</a></li><li><a class="nounderline abstract_t">Bosch F, López-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82:567.</a></li><li><a class="nounderline abstract_t">Fisher RI, Dahlberg S, Nathwani BN, et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995; 85:1075.</a></li><li><a class="nounderline abstract_t">Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989; 7:365.</a></li><li><a class="nounderline abstract_t">Berger F, Felman P, Sonet A, et al. Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. Blood 1994; 83:2829.</a></li><li><a class="nounderline abstract_t">Matutes E, Parry-Jones N, Brito-Babapulle V, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma 2004; 45:2007.</a></li><li><a class="nounderline abstract_t">Räty R, Franssila K, Jansson SE, et al. Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma. Eur J Cancer 2003; 39:321.</a></li><li><a class="nounderline abstract_t">Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131:29.</a></li><li><a class="nounderline abstract_t">Katzenberger T, Petzoldt C, Höller S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006; 107:3407.</a></li><li><a class="nounderline abstract_t">Garcia M, Romaguera JE, Inamdar KV, et al. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer 2009; 115:1041.</a></li><li><a class="nounderline abstract_t">Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111:558.</a></li><li><a class="nounderline abstract_t">Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115:1530.</a></li><li><a class="nounderline abstract_t">Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol 2014; 32:1338.</a></li><li><a class="nounderline abstract_t">Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150:200.</a></li><li><a class="nounderline abstract_t">Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158:355.</a></li></ol></div><div id="topicVersionRevision">Topic 4702 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27618563" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2016 US lymphoid malignancy statistics by World Health Organization subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767440" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mantle-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664057" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22045184" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18615506" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8068936" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2070063" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : bcl-1, t(11;14), and mantle cell-derived lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12515730" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8623927" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637326" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12511405" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12842981" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12609845" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15257315" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1535701" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18787224" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29045844" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864294" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11468180" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30963600" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14724650" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15784165" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The activation of Akt/PKB signaling pathway and cell survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19879843" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : PI3 kinase signals BCR-dependent mature B cell survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645163" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12816986" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24362935" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23782157" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28819011" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32160292" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32072136" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12548600" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17001159" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8978336" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D'étude des Lymphomes Digestifs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2665536" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Multiple lymphomatous polyposis of the gastrointestinal tract. A clinicopathologically distinctive form of non-Hodgkin's lymphoma of B-cell centrocytic type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19694718" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23616279" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29246179" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Smoldering mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29246179" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Smoldering mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34297045" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299095" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29773591" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : t(11;14)-positive mantle cell lymphomas lacking cyclin D1 (CCND1) immunostaining because of a CCND1 mutation or exclusive expression of the CCND1b isoform.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391076" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16123218" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22490335" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421449" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23255553" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580957" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580957" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19880778" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25229384" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Utility and diagnostic pitfalls of SOX11 monoclonal antibodies in mantle cell lymphoma and other lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145648" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8079114" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Multiple lymphomatous polyposis of the colon and rectum. Report of a case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10333231" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Multiple lymphomatous polyposis of the gastrointestinal tract is a heterogenous group that includes mantle cell lymphoma and follicular lymphoma: analysis of somatic mutation of immunoglobulin heavy chain gene variable region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29196411" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29396091" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24684350" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36725119" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment approaches for patients with TP53-mutated mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32748433" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393178" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Aggressive lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10319386" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Genetics of small lymphocyte disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15718413" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10361135" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17391491" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22210878" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145436" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16155021" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23407552" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24682267" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18483394" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18552173" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Correlation of cyclin D1 transcript levels, transcript type and protein expression with proliferation and histology among mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21945515" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The complex landscape of genetic alterations in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31753927" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31015206" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23321250" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23520328" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : SOX11 is a mantle cell lymphoma oncogene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1987908" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Histopathologic features of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427703" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34882582" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10329598" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2002419" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Translocation (11;14): a cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26926679" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28961827" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Observation as the initial management strategy in patients with mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19669190" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22915760" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32584970" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29769262" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30768440" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31975037" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22425896" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28457696" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791422" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29129357" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : In situ neoplasia in lymph node pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22058203" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18381689" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The cut-off levels of CD23 expression in the differential diagnosis of MCL and CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33324951" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : CCND1 Genomic Rearrangement as a Secondary Event in High Grade B-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9166827" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9452276" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7849295" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2670728" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8180379" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15370245" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12565984" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173960" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16597597" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19170236" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17962512" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20032504" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687837" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20528872" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22640180" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
